FDA Approves Leniolisib for Children 4 to 11 Years With APDS

The FDA has approved Leniolisib for treating children aged 4 to 11 with Activated PI3K Delta Syndrome (APDS), expanding treatment options for this rare immune disorder in pediatric patients.

This Wire brief sits within Fusion42's coverage of Biotech.